#### 1 **Type of article:** Systematic review article

### 2 Title of the article: Clinical Virology and Effect of Vaccination and Monoclonal Antibodies

#### against SARS-CoV-2 Omicron Sub Variant BF.7 (BA.5.2.1.7) : A systematic review.

Name of the Authors: Santenna Chenchula\*<sup>1</sup>, Krishna Chaitanya Amarneni, Mohan Krishna
Ghanta, Padmavathi R<sup>2</sup>, Madhu Bhargavi Chandra, Madhu Babu Adusumilli , Madhavrao
Chavan<sup>1</sup>, Sofia Mudda, Rupesh Gupta, Bhawna Lakhawat.

#### 7 Running Title: The BF.7 (BA.5.2.1.7) variant Virology and Preventing Strategies.

#### 8 The affiliation(s) of the author(s):

- 9 1. \*Santenna Chenchula, PhD, Department of Pharmacology, All India Institute of
   Medical Sciences (AIIMS)Bhopal, Madhya Pradesh, India. Email: csanten7@gmail.com
- Krishna Chaitanya Amarneni, Faculty, Western Michigan University, Kalamazoo,
   Michigan. Email: krishnachaitanya.amerneni@med.wmich.edu
- Mohan Krishna Ghanta, Assistant Professor, Department of Pharmacology, MVJ
   Medical College and Research Hospital, Bangalore, Karnataka, Email:
   mohanakrishna.ghanta@gmail.com
- Padmavathi R, Resident, SVS Medical College and Hospital, Telangana, India. Email:
   pad.mythili@gmail.com
- 18 5. Madhu Bhargavi Chandra, Intern, All India Institute of Medical sciences, Bhopal.
  19 email: <u>madhubhargavi196@gmail.com</u>
- 6. Madhu Babu Adusumilli, Intern, All India Institute of Medical sciences, Bhopal. email:
   madhu.adusumilli3@gmail.com
- 22 7. Sofia Mudda, Medical Officer, All India Institute of Medical sciences, Bhopal. Email:
   23 sophia.dr@gmail.com

- 8. Madhavrao Chavan, Department of Pharmacology, All India Institute of Medical
- 25 Sciences (AIIMS) Mangalagiri, Andhra Pradesh, India. Email:
- 26 <u>madhavrao.pharm@aiimsmangalagiri.edu.in</u>
- Rupesh Gupta, Assistant Professor, Department of Internal Medicine, Government
   Medical College, Shahdol, Madhyapradesh, India. Email: <u>neolog.raj@gmail.com</u>
- 29 10. Bhawna Lakhawat , Tutor, department of Pharmacology, All India Institute of Medical
- 30 sciences, Bhopal, Email: bhawnaajmer001@gmail.com
- 31 **\*Corresponding Author**: Santenna Chenchula, Department of Pharmacology, 3<sup>rd</sup> floor, All
- 32 India Institute of Medical Sciences, Bhopal,462020, Madhya Pradesh, India.
- 33 **Phone no:** 7987220348
- 34 **Email Id:** csanten7@gmail.com.
- 35 **The total number of pages**:10.
- 36 Total number of Tables/Graphs:0
- 37 Total number of Images: 0
- 38 Word counts: For abstract: 187
- **For the text**: 2133
- 40 Prior publication: Nil
- 41 Sources of Support: Nil
- 42 Conflicts of interest: Nil
- 43 Read and approved by all authors: Yes.

44

45

- 46
- 40
- 47

#### 48 Abstract:

49 Since its identification in late 2019 the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) In Wuhan, China, by the World Health Organization (WHO), 50 51 which cause the coronavirus disease 2019, it is rapidly spreading, resulting in the global 52 pandemic. As of 19 December 2022, more than 64 million confirmed cases and 6,645,812 deaths have been reported across the world. Over time, the SARS-CoV-2 acquired genetic 53 mutations resulting in multiple types of SARS-CoV-2 variants and subvariants that have been 54 confirmed. The Omicron (B.1.1.529) variant was identified later in November 2021, with 55 enhanced immune escape and was followed with various sublineages due to mutations in the 56 57 spike protein of the SARS-CoV-2. However, rapid resurge in COVID-19 reports by Omicron subvariant BF.7(BA.2.75.2) in China and other countries, alarming global threat. The present 58 systematic review was conducted using "Omicron" AND "BA.5.2.1.7" OR "BF.7" in Pub Med, 59 60 Google Scholar and MedRXiv database and grey literature from the authentic database and websites. We have identified a total of 14 published studies. We have reviewed all the eligible 61 available studies to understand the viral mutations, factors associated with increase in the reports 62 of COVID-19 cases in china and across the world and to evaluate the effectiveness of 63 vaccination and monoclonal antibodies against BF.7 variant. 64

- 65
- 66
- 67
- 68
- 69 **Introduction:**
- 70

**Text File** 

71 Since its identification in late 2019 the novel coronavirus, severe acute respiratory syndrome 72 coronavirus 2 (SARS-CoV-2) In Wuhan, China, by the World Health Organization (WHO), which cause the coronavirus disease 2019, it is rapidly spreading, resulting in the global 73 74 pandemic [1]. As of 19 December 2022, . As of 19 December 2022, more than 64 million confirmed cases and 6,645,812 deaths have been reported across the world [2]. Over time, the 75 SARS-CoV-2 acquired genetic mutations resulting in multiple types of SARS-CoV-2 variants 76 77 and subvariants that have been confirmed [3]. Certain variants have gained keen attention because of their characteristics of rapid transmissibility, enhanced immune escape and severity 78 79 of the infection and these are considered variants of concern (VOC) that continue to threaten public health [3]. 80

Later in November 2021, the Omicron (B.1.1.529) variant with enhanced immune escape was 81 first reported from Botswana and thereafter from South Africa with an increased infection [3-4]. 82 Very soon it has been spread swiftly to several other countries, across the world with subtle raise 83 in the number of COVID-19 infections [4-5]. Subsequently, Omicron sublineages with 84 increasingly greater replication advantages emerged, replacing the previous predominant 85 sublineage [3]. There are about 200 sublineages of Omicron [3]. The original Omicron variant 86 87 was sublineage BA.1, BA.2, BA.3, BA.4 and BA.5 [5-6]. Other Omicron sublineages, such as BQ.1, BQ.11, BF.7, BA.2.75, and XBB, which evolved from various previously circulating 88 89 sublineages, have been increasing in prevalence worldwide [7]. Each sublineage differs from the 90 others by several mutations in the spike protein except for BA.4 and BA.5, which have identical spike proteins [8]. Evidence has shown that, all omicron sub-variants are distinct from pre-91 92 omicron variants, including BA.1, BA.2 and BA.5 omicron sub-variants are also antigenically distinct from each other [9]. 93

In response to the current surge in the COVID-19 reports by Omicron subvariant BF.7 also known as BA.2.75.2 in China and other countries, triggering global alarm the present review was conducted to understand the virology, factors associated with increased reports of COVID-19 infections with BF.7 variant in China and possible urgent preventing strategies to be taken to curtail the novel omicron variants outbreak across the world.

99

100 Methodology:

We have performed a comprehensive literature search was performed from inception to till 101 102 January 2022, using the MeSH terms and keywords "Omicron" AND "BA.5.2.1.7" OR "BF.7" in 103 Pub Med, Google Scholar and MedRXiv database and grey literature from the authentic database 104 and websites to find relative information about Omicron subvariant BF.7 (BA.5.2.1.7) and data 105 assessed to understand viral mutations, factors associated with increased reports of COVID-19 106 infections with BF.7 variant in china and on literature evidence on vaccine effectiveness and 107 monoclonalantibodies against BF.7 to understand possible urgent preventing strategies to be taken to curtail the novel omicron variants outbreak in china and across the world. 108

109

#### 110 **Results:**

In the present review, after removing duplications and literature not mentioned regarding BF.7 or BA.5.2.1.7, a total of 14 studies were found eligible among the 79 studies. The SARS-CoV-2 Omicron BF.7 (BA.5.2.1.7) a subvariant of BA.5, is responsible for the ongoing resurgence of cases since late September 2022 in China [10].To date, BF.7 (BA.5.2.1.7) subvariant has been

reported in Belgium, China, Denmark, Norway, France, Germany, India, Mongolia, the United Kingdom and the United States[11-12]. However, Before China, the BF.7 variant has been circulating at an incredibly intense level in USA and Europe since August 2022[8-10]. The current reports from China indicate BF.7 has the strongest infection ability out of the Omicron subvariants, being quicker to transmit than other variants, having a shorter incubation period, and with a greater capacity to infect people who have had a previous COVID infection, or been vaccinated, or both [11].

122 The most symptoms of an infection with BF.7 were similar to those associated with other 123 Omicron subvariants, primarily upper respiratory symptoms[12].Patients may have a fever, 124 cough, sore throat, running nose and fatigue, among other symptoms and gastrointestinal symptoms like vomiting and diarrhoea [11-12]. The basic reproduction number Rt of omicron 125 BF.7(BA.5.2.1.7) variant was 10 to 18.6. which is significantly high compared to BA.1 Omicron 126 variant which is only 5.08[11]. A study by Kathy Leung et al., in china during November to 127 December 2022 found that, the Rt increased to 3.42 (95% CrI: 2.79 - 4.17) on November 18, 128 Infection incidence peaked on December 10, and the cumulative infection attack rate was 42.5% 129 (95% CrI: 20.3 - 63.9) on December 14[13]. The high transmission rate of BF.7(BA.5.2.1.7), is 130 131 due to the novel mutations in the spike protein [11-15]. Evidence from the Molecular modelling revealed the mechanisms of antibody-mediated immune evasion by R346T, K444T, F486S, and 132 133 D1199N mutations on the receptor-binding domain [15]. However, the omicron variant BF.7 carries an additional specific mutation, R346T in the spike protein of SARS-CoV-2 which is 134 135 derived from the BA.4/5 subvariant, which is why the BF.7 variant has a 4.4-fold higher neutralization resistance than the original D614G variant [15]. The Arg346 mutations R346T in 136 the BF.7 variant spike glycoprotein, particularly those on the receptor-binding domain has been 137

138 associated with an increased immune escape capability to neutralize antibodies generated by 139 vaccines or previous infection[11-15]. Therefore, COVID-19 infection with BF.7 variant may cause a serious illness in populations with weaker immune systems such as the elderly and those 140 141 with concomitant comorbidities [13-15]. A study by Wang, Qian et al., investigated the sensitivity profile of omicron subvariants to neutralisation by a panel of 23 mAbs found that, all 142 mAbs retained potency against earlier omicron subvariants, including that targeted different 143 epitope clusters of the receptor-binding domain (RBD) of the viral spike and others that target 144 non-RBD epitopes [16]. The neutralisation profiles of BF.7 did not differ much from that of 145 146 BA.4/5 except those mAbs in RBD class 3 which showed substantial reduction in their 147 neutralisation potency against the new subvariants [16]. The reduced neutralizing activity was mainly due to mutation R346T, R346S, or R346I, which are associated with eliminated or 148 weakened hydrogen bonds or salt bridges, or both, between R346 and some RBD class 3 mAbs. 149 150 In addition, the combination of a monoclonal antibodies cilgavimab and tixagevimab, which had 151 received an emergency use authorisation for the prevention of COVID-19, could also not 152 neutralized BF.7 and other variants such as, BA.4.6, BA.4.7, and BA.5.9[16].

#### 153 **Discussion:**

Being quicker to transmit than other Omicron variants, having a shorter incubation period, increased evasion of antibodies and with greater capacity to infect people who have had a previous COVID-19 infection, and/or been vaccinated, or both, the BF.7 variant is causing a significant increase in number COVI-19 cases in China and across the world [16-17]. A SARS-CoV-2 transmission model study by Kathy Leung et al., from China, using the data from recent outbreaks in Hong Kong and Shanghai to compare different scenarios in China concluded that the hospitals will be overwhelmed if infections rise as rapidly because of the easing of Zero

161 COVID policy restrictions and will probably result in about one million deaths over the next few 162 months, the study forecasts [17]. The study also suggests that, if 85% of the population gets a booster fourth dose of the COVID -19 vaccine other than the inactivated-virus vaccines, it could 163 164 slow the rise in infections and reduce the number of severe infections and deaths by up to 35% [17]. According to this study, if China lifts the zero-COVID policy the Omicron could infect 165 between 160 million and 280 million people and 1.55 million deaths largely among 166 unvaccinated older adults [17]. The study also suggests that, if 85% of the population gets the 167 fourth dose of a vaccine other than the inactivated-virus vaccine could slow the increase in 168 169 infections, the number of severe infections and deaths [17]. According to reports from China, more than 90% of the population has been fully vaccinated [18]. However, less than half of 170 people aged 80 and over have received three doses of the vaccine [18]. Evidence also shown that, 171 172 the inactivated vaccine CoronaVac from China produced lower levels of neutralizing antibodies and these antibody levels also dropped quickly over time [18]. In addition, studies also have 173 174 shown that protection from severe disease was also very less in preventing severe disease and 175 death among 80 years and older [17].

176 Evidence from the literature suggests that booster vaccination is associated with a significant impact on emerging Omicron variants across the world. A study by Sullivan, David J et al., to 177 evaluate polyclonal antibodies from individuals both with at least 3 vaccine doses and also 178 179 recently recovered from Omicron COVID-19 (VaxCCP) neutralizing activity against new 180 Omicron lineages in 740 individual patient samples from 37 separate cohorts defined by boosted 181 vaccinations with or without recent Omicron COVID-19, as well as infection without vaccination found that more than 96% of the plasma samples from individuals in the recently i.e., 182 183 within 6 months boosted VaxCCP study cohorts neutralized BQ.1.1 with 79%, XBB.1 with 22%

184 and BF.7 with 94% variants respectively [19]. Another study by Sullivan DJ et al., on found 185 that, the BA.5-bivalent booster dose vaccines elicited better neutralization against the newly emerged Omicron sublineages including BF.7 variant than the parental mRNA vaccine and those 186 187 individuals with SARS-CoV-2 infection history develop higher and broader neutralization antibodies against the ongoing novel Omicron sublineages after the BA.5-bivalent booster [20]. 188 Another study by Zhu, Ka-Li Jiang et al., found that, two-dose CoronaVac or a third-dose 189 190 ZF2001 booster elicits limited neutralization against Omicron subvariants 6 months after vaccination but hybrid immunity as well as Delta, BA.1, and BA.2 breakthrough infections 191 192 induced long-term persistence of the antibody response, and over 70% of sera neutralized BF.7. as well as BA.1, BA.2, BA.4/BA.5[21]. Another systematic review of effect of booster dose 193 vaccination, with 27 studies by Chenchula S et al., found that, booster-dose vaccine efficacy 194 against SARS-CoV-2 variants, including Omicron sublineages [22]. 195

#### 196 **Conclusion:**

The present review focusing on the variant of concern Omicron BF.7 with enhanced infectivity 197 and transmissibility potential suggests that in addition to regular surveillance activities, the 198 protection strategies need to rapidly achieve by global vaccination to nonvaccinated populations 199 200 and booster dose vaccination with other than inactivated vaccines, especially among 201 immunocompromised and vulnerable populations those aged 60 years more and in children, to 202 prevent possible outbreaks of novel SARS-CoV-2 Omicron subvariants and to decrease severity 203 and mortality to mitigate the healthcare and economic impacts due to the emerging Omicron 204 sublineages and future VOCs.

9

#### 205 Acknowledgment:

- 206 None to declare.
- 207 **Conflict of Interests:** The authors declare that there are no conflicts of interests.
- 208 Grants and funding: None.

209 Author Contributions: Santenna Chenchula conducted the literature search and data extraction

and drafted the manuscript. Krishna Chaitanya Amarneni, Mohan Krishna Ghanta, Padmavathi

- 211 R, Madhu Bhargavi Chandra, Madhu Babu Adusumilli, Bhawna Lakhawat, Madhavrao Chavan,
- 212 Sofia Mudda, Rupesh Gupta revised the final manuscript. All authors reviewed and approved the
- 213 final version of the manuscript.

#### 214 Data Availability:

The data used in this systematic review is available from the corresponding author with a reasonable request.

#### 217 **References:**

218

WHO Coronavirus (COVID-19) dashboard. https://covid19.who.int/. Accessed: 20
 December 2022.

221 2. WHO Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. Statement 26

- November, 2021.Accessed: 20 December, 2022: https://www.who.int/news/item/26-11-
- 223 2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.

- 224 3. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available from:
- https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-
- 226 2-variant-of-concern. Accessed on: 20 December 2022.
- 4. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2
  Omicron variant in southern Africa. Nature. 2022;603(7902):679-686.
- 5. Arora P, Zhang L, Rocha C, et al. Comparable neutralisation evasion of SARS-CoV-2
  omicron subvariants BA.1, BA.2, and BA.3. Lancet Infect Dis. 2022;22(6):766-767.
- 6. Rössler A, Netzl A, Knabl L, Schäfer H, Wilks SH, Bante D, et al . BA.2 and BA.5 omicron
- differ immunologically from both BA.1 omicron and pre-omicron variants. Nat Commun.

233 2022 Dec 13;13(1):7701. doi: 10.1038/s41467-022-35312-3.

234 7. Implications of the emergence and spread of the SARS-CoV-2 variants of concern BA.4 and

BA.5 for the EU/EEA. European Centre for Disease Prevention and Control. Available at:

- https://www.ecdc.europa.eu/en/news-events/implications-emergence-spread-sars-cov-2-
- variants-concern-ba4-and-ba5. Accessed on 20 December, 2022.
- 8. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E et al., Emergence of
   SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28(9):1785.
- 240 9. Jian F, Yu Y, Song W, Yisimayi A, Yu L, Gao Y, et al. Further humoral immunity evasion of
- emerging SARS-CoV-2 BA.4 and BA.5 subvariants. Lancet Infect Dis. 2022
  Nov;22(11):1535-1537. doi: 10.1016/S1473-3099(22)00642-9.
- 10. Mallapaty S. Can China avoid a wave of deaths if it lifts strict zero COVID policy? Nature.
- 244 2022 ;612(7939):203. doi: 10.1038/d41586-022-04235-w.

245	11. BF.7: What to know about the Omicron COVID variant. Available at :			
246	https://www.cbsnews.com/news/bf7-new-omicron-coronavirus-variant-covid/. Accesed on			
247	20 December 20222.			
248	12. Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And Novel			
249	Therapeutics Against Coronavirus (COVID-19). 2022 Oct 10. In: StatPearls [Internet].			
250	Treasure Island (FL): StatPearls Publishing; 2022 Jan PMID: 34033342.			
251	13. Kathy Leung, Eric H. Y. Lau, Carlos K. H. Wong, Gabriel M. Leung, Joseph T. Wu.			
252	Estimating the transmission dynamics of Omicron in Beijing, November to December			
253	2022.medRxiv 2022.12.15.22283522; doi: https://doi.org/10.1101/2022.12.15.22283522.			
254	14. SARS-CoV-2 Omicron BF.7 variant. Available at : https://en.wikipedia.org/wiki/SARS-			
255	CoV-2_Omicron_BF.7_variant. Accessed on 20 December 2022.			
256	15. Qu P, Evans JP, Faraone JN, Zheng YM, Carlin C, Anghelina M, et al. Enhanced			
257	neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7,			
258	and BA.2.75.2. Cell Host Microbe. 2022 Nov 22:S1931-3128(22)00568-6. doi:			
259	10.1016/j.chom.2022.11.012.			
260	16. Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Mohri H, Liu M, Wang M, Yu J, Shah JG, Chang JY,			
261	Herbas F, Yin MT, Sobieszczyk ME, Sheng Z, Liu L, Ho DD. Resistance of SARS-CoV-2			
262	omicron subvariant BA.4.6 to antibody neutralisation. Lancet Infect Dis. 2022			
263	Dec;22(12):1666-1668. doi: 10.1016/S1473-3099(22)00694-6.			
264	17. Cai J, Deng X, Yang J, Sun K, Liu H, Chen Z, et al . Modeling transmission of SARS-CoV-2			
265	Omicron in China. Nat Med. 2022 Jul;28(7):1468-1475. doi: 10.1038/s41591-022-01855-7.			
266	18. China Covid: What is China's policy and how many cases are there?.BBC: Reality check.			
267	Available from: https://www.bbc.com/news/59882774. Accessed on 20 December 2022.			

12

	19. Mallapaty S. China's COVID vaccines have been crucial - now immunity is waning. Nature			
269	2021 Oct;598(7881):398-399. doi: 10.1038/d41586-021-02796-w.			
270	20. Sullivan DJ, Franchini M, Senefe	eld JW, Joyner MJ, Ca	sadevall A, Focosi D. Plasm	na after
271	both SARS-CoV-2 boosted vacc	cination and COVID-1	9 potently neutralizes BQ.1	.1 and
272	XBB.1. bioRxiv [Preprin	t]. 2022 Nov	30:2022.11.25.517977.	doi:
273	10.1101/2022.11.25.517977.			
274	21. Zhu, Ka-Li Jiang, Xiao-Lin Wan	ng, Xue-Jun Xia, Xian	Zhan, Bing-Dong Cao, Gu	io-Ping
275	Wang, et al.,.Durability of Neut	ralization Against Omi	cron Subvariants after Vacc	ination
		-		
276	and Breakthrough	Infection.	Available	at
276 277	and Breakthrough SSRN: <u>https://ssrn.com/abstract=4</u>	Infection. 1281072 or <u>http://dx.doi</u>	Available .org/10.2139/ssrn.4281072	at
276 277 278	and Breakthrough SSRN: <u>https://ssrn.com/abstract=4</u> 22. Chenchula S, Karunakaran P, S	Infection. 1281072 or <u>http://dx.doi</u> Sharma S, Chavan M.	Available .org/10.2139/ssrn.4281072 Current evidence on effic	at acy of
276 277 278 279	and Breakthrough SSRN: <u>https://ssrn.com/abstract=4</u> 22. Chenchula S, Karunakaran P, S COVID-19 booster dose vaccina	Infection. 1281072 or <u>http://dx.doi</u> Sharma S, Chavan M. tion against the Omicr	Available .org/10.2139/ssrn.4281072 Current evidence on effic on variant: A systematic rev	at acy of view. J
276 277 278 279 280	and Breakthrough SSRN: https://ssrn.com/abstract=4 22. Chenchula S, Karunakaran P, S COVID-19 booster dose vaccina Med Virol. 2022 ;94(7):2969-2976	Infection. 1281072 or <u>http://dx.doi</u> Sharma S, Chavan M. tion against the Omicr 6. doi: 10.1002/jmv.276	Available .org/10.2139/ssrn.4281072 Current evidence on effic on variant: A systematic rev 97.	at acy of view. J
276 277 278 279 280 281	and Breakthrough SSRN: <u>https://ssrn.com/abstract=4</u> 22. Chenchula S, Karunakaran P, S COVID-19 booster dose vaccina Med Virol. 2022 ;94(7):2969-2976	Infection. 1281072 or <u>http://dx.doi</u> 3harma S, Chavan M. tion against the Omicr 5. doi: 10.1002/jmv.276	Available .org/10.2139/ssrn.4281072 Current evidence on effic on variant: A systematic rev 97.	at acy of view. J

# Figure 1: PRISMA Flow Diagram for the study selection.

Identification of studies via in Pub Med, Google Scholar and MedRXiv by Using Following MESH or Key words

## "Omicron" AND "BA.5.2.1.7" OR "BF.7"

